About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2010 (2010), Article ID 357591, 6 pages
http://dx.doi.org/10.1155/2010/357591
Review Article

Mycobacterium bovis Bacillus Calmette-Guérin-Induced Macrophage Cytotoxicity against Bladder Cancer Cells

Department of Urology, University of Iowa, 375 Newton Road, 3202 MERF, Iowa City, IA 52242, USA

Received 15 June 2010; Accepted 16 August 2010

Academic Editor: Bernhard Fleischer

Copyright © 2010 Yi Luo and Matthew J. Knudson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Morales, D. Eidinger, and A. W. Bruce, “Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors,” Journal of Urology, vol. 116, no. 2, pp. 180–183, 1976. View at Scopus
  2. A. B. Alexandroff, A. M. Jackson, M. A. O'Donnell, and K. James, “BCG immunotherapy of bladder cancer: 20 years on,” Lancet, vol. 353, no. 9165, pp. 1689–1694, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Patard, F. Saint, F. Velotti, C. C. Abbou, and D. K. Chopin, “Immune response following intravesical bacillus Calmette-Guerin instillations in superficial madder cancer: a review,” Urological Research, vol. 26, no. 3, pp. 155–159, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. T. L. Ratliff, J. K. Ritchey, J. J. J. Yuan, G. L. Andriole, and W. J. Catalona, “T-cell subsets required for intravesical BCG immunotherapy for bladder cancer,” Journal of Urology, vol. 150, no. 3, pp. 1018–1023, 1993. View at Scopus
  5. R. Wang, A. M. Rogers, T. L. Ratliff, and J. H. Russell, “CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors,” Journal of Immunology, vol. 157, no. 7, pp. 2961–2968, 1996. View at Scopus
  6. S. Brandau, J. Riemensberger, and J. Riemensberger, “NK cells are essential for effective BCG immunotherapy,” International Journal of Cancer, vol. 92, no. 5, pp. 697–702, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Liu, M. A. O'Donnell, X. Chen, R. Han, and Y. Luo, “Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro,” Cancer Immunology, Immunotherapy, vol. 58, no. 10, pp. 1647–1655, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M.-H. Wang, H.-D. Flad, A. Böhle, Y.-Q. Chen, and A. J. Ulmer, “Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines,” Immunology Letters, vol. 27, no. 3, pp. 191–198, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. Shemtov, D. L.-W. Cheng, L. Kong, W.-P. Shu, M. Sassaroli, M. J. Droller, and B. C.-S. Liu, “LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy,” Journal of Urology, vol. 154, no. 1, pp. 269–274, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Thanhäuser, A. Böhle, H.-D. Flad, M. Ernst, T. Mattern, and A. J. Ulmer, “Induction of bacillus-Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro,” Cancer Immunology Immunotherapy, vol. 37, no. 2, pp. 105–111, 1993. View at Scopus
  11. S. Brandau, H. Suttmann, and H. Suttmann, “Perforin-mediated lysis of tumor cells by Mycobacterium Bovis Bacillus Calmette-Guerin-activated killer cells,” Clinical Cancer Research, vol. 6, no. 9, pp. 3729–3738, 2000. View at Scopus
  12. A. Böhle, A. Thanhäuser, A. J. Ulmer, M. Ernst, H.-D. Flad, and D. Jocham, “Dissecting the immunobiological effects of Bacillus Calmette-Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon,” Journal of Urology, vol. 150, no. 6, pp. 1932–1937, 1993. View at Scopus
  13. T. Kawashima, Y. Norose, and Y. Norose, “Cutting edge: major CD8 T cell response to live bacillus Calmette-Guérin is mediated by CD1 molecules,” Journal of Immunology, vol. 170, no. 11, pp. 5345–5348, 2003. View at Scopus
  14. M.-H. Wang, Y.-Q. Chen, J. Gercken, M. Ernst, A. Böhle, H.-D. Flad, and A. J. Ulmer, “Specific activation of human peripheral blood γ/δ+ T lymphocytes by sonicated antigens of Mycobacterium tuberculosis: role in vitro in killing human bladder carcinoma cell lines,” Scandinavian Journal of Immunology, vol. 38, no. 3, pp. 239–246, 1993. View at Scopus
  15. T. Higuchi, M. Shimizu, A. Owaki, M. Takahashi, E. Shinya, T. Nishimura, and H. Takahashi, “A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth,” Cancer Immunology, Immunotherapy, vol. 58, no. 8, pp. 1245–1255, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. Naoe, Y. Ogawa, K. Takeshita, J. Morita, S. Iwamoto, A. Miyazaki, and H. Yoshida, “Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and γδT cells,” International Journal of Urology, vol. 14, no. 6, pp. 532–538, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. Emoto, Y. Emoto, I. B. Buchwalow, and S. H. E. Kaufmann, “Induction of IFN-γ-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guerin,” European Journal of Immunology, vol. 29, no. 2, pp. 650–659, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Suttmann, J. Riemensberger, and J. Riemensberger, “Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses,” Cancer Research, vol. 66, no. 16, pp. 8250–8257, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. H. M. Rosevear, A. J. Lightfoot, M. A. O'Donnell, and T. S. Griffith, “The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder,” Cancer Metastasis Reviews, vol. 28, no. 3-4, pp. 345–353, 2009.
  20. J. Klostergaard, P. A. Stoltje, and F. C. Kull Jr., “Tumoricidal effector mechanisms of murine BCG-activated macrophages: role of TNF in conjugation-dependent and conjugation-independent pathways,” Journal of Leukocyte Biology, vol. 48, no. 3, pp. 220–228, 1990. View at Scopus
  21. J. Klostergaard, M. E. Leroux, and M.-C. Hung, “Cellular models of macrophage tumoricidal effector mechanisms in vitro. Characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro,” Journal of Immunology, vol. 147, no. 8, pp. 2802–2808, 1991. View at Scopus
  22. G. Schwamberger, I. Flesch, and E. Ferber, “Tumoricidal effector molecules of murine macrophages,” Pathobiology, vol. 59, no. 4, pp. 248–253, 1991. View at Scopus
  23. A. Böhle, J. Gerdes, A. J. Ulmer, A. G. Hofstetter, and H.-D. Flad, “Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall,” Journal of Urology, vol. 144, no. 1, pp. 53–58, 1990. View at Scopus
  24. S. Prescott, K. James, T. B. Hargreave, G. D. Chisholm, and J. F. Smyth, “Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall,” Journal of Urology, vol. 147, no. 6, pp. 1636–1642, 1992. View at Scopus
  25. M. Peuchmaur, G. Benoit, A. Vieillefond, A. Chevalier, G. Lemaigre, E. D. Martin, and A. Jardin, “Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus calmette-guerin,” Urological Research, vol. 17, no. 5, pp. 299–303, 1989. View at Scopus
  26. F. Saint, J. J. Patard, B. Groux Muscatelli, M. A. Lefrere Belda, S. Gil Diez De Medina, C. C. Abbou, and D. K. Chopin, “Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment,” British Journal of Urology International, vol. 88, no. 6, pp. 602–610, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. E. C. De Boer, W. H. De Jong, and W. H. De Jong, “Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis,” Urological Research, vol. 19, no. 1, pp. 45–50, 1991. View at Scopus
  28. E. C. De Boer, W. H. De Jong, and W. H. De Jong, “Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin,” Cancer Immunology Immunotherapy, vol. 33, no. 6, pp. 411–416, 1991. View at Scopus
  29. E. C. De Boer, W. H. De Jong, P. A. Steerenberg, A. P. M. Van Der Meijden, L. A. Aarden, F. M. J. Debruyne, and E. J. Ruitenberg, “Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with Bacillus Calmette-Guerine,” In Vivo, vol. 5, no. 6, pp. 671–678, 1991. View at Scopus
  30. A. Böhle, N. CH. Nowc, A. J. Ulmer, J. Musehold, J. Gerdes, A. G. Hofstetter, and H.-D. Flad, “Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy,” Journal of Urology, vol. 144, no. 1, pp. 59–64, 1990. View at Scopus
  31. G. N. Thalmann, A. Sermier, C. Rentsch, K. Möhrle, M. G. Cecchini, and U. E. Studer, “Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin,” Journal of Urology, vol. 164, no. 6, pp. 2129–2133, 2000. View at Scopus
  32. T. M. De Reijke, E. C. De Boer, K. H. Kurth, and D. H. J. Schamhart, “Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value,” Journal of Urology, vol. 155, no. 2, pp. 477–482, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Saint, J. J. Patard, and J. J. Patard, “Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer,” Journal of Urology, vol. 167, no. 1, pp. 364–367, 2002. View at Scopus
  34. R. Nadler, Y. Luo, and Y. Luo, “Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity,” Clinical and Experimental Immunology, vol. 131, no. 2, pp. 206–216, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Luo, X. Chen, and M. A. O'Donnell, “Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo,” Clinical and Experimental Immunology, vol. 147, no. 2, pp. 370–378, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. J. Wang, J. Wakeham, R. Harkness, and Z. Xing, “Macrophages are a significant source of type 1 cytokines during mycobacterial infection,” Journal of Clinical Investigation, vol. 103, no. 7, pp. 1023–1029, 1999. View at Scopus
  37. S. Atkinson, E. Valadas, S. M. Smith, P. T. Lukey, and H. M. Dockrell, “Monocyte-derived macrophage cytokine responses induced by M. bovis BCG,” Tubercle and Lung Disease, vol. 80, no. 4-5, pp. 197–207, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. L. Calorini, F. Bianchini, A. Mannini, G. Mugnai, M. Balzi, A. Becciolini, and S. Ruggieri, “IFNγ and TNFα account for a pro-clonogenic activity secreted by activated murine peritoneal macrophages,” Clinical and Experimental Metastasis, vol. 19, no. 3, pp. 259–264, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Baran, M. Baj-Krzyworzeka, K. Weglarczyk, I. Ruggiero, and M. Zembala, “Modulation of monocyte-tumour cell interactions by Mycobacterium vaccae,” Cancer Immunology, Immunotherapy, vol. 53, no. 12, pp. 1127–1134, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Pryor, J. Goddard, D. Goldstein, P. Stricker, P. Russell, D. Golovsky, and R. Penny, “Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing,” British Journal of Cancer, vol. 71, no. 4, pp. 801–807, 1995. View at Scopus
  41. H. Yamada, S. Matsumoto, T. Matsumoto, T. Yamada, and U. Yamashita, “Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2,” Journal of Urology, vol. 164, no. 2, pp. 526–531, 2000. View at Scopus
  42. H. Yamada, S. Matsumoto, T. Matsumoto, T. Yamada, and U. Yamashita, “Enhancing effect of an inhibitor of nitric oxide synthesis on Bacillus Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro,” Japanese Journal of Cancer Research, vol. 91, no. 5, pp. 534–542, 2000. View at Scopus
  43. H. Yamada, E. Kuroda, S. Matsumoto, T. Matsumoto, T. Yamada, and U. Yamashita, “Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro,” Clinical and Experimental Immunology, vol. 128, no. 1, pp. 52–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Luo, H. Yamada, X. Chen, A. A. Ryan, D. P. Evanoff, J. A. Triccas, and M. A. O'Donnell, “Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augmente Th1 immunity and macrophage cytotoxicity,” Clinical and Experimental Immunology, vol. 137, no. 1, pp. 24–34, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. Y. Luo, H. Yamada, D. P. Evanoff, and X. Chen, “Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells,” Clinical and Experimental Immunology, vol. 146, no. 1, pp. 181–188, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. Y. Luo, R. Han, D. P. Evanoff, and X. Chen, “Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells,” Clinical and Experimental Immunology, vol. 160, no. 3, pp. 359–368, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. T. L. Ratliff, “Bacillus Calmette-Guerin (BCG): mechanism of action in superficial bladder cancer,” Urology, vol. 37, no. 5, supplement, pp. 8–11, 1991. View at Scopus
  48. R. F. M. Bevers, K.-H. Kurth, and D. H. J. Schamhart, “Role of urothelial cells in BCG immunotherapy for superficial bladder cancer,” British Journal of Cancer, vol. 91, no. 4, pp. 607–612, 2004. View at Scopus
  49. W. L. Smith, R. M. Garavito, and D. L. DeWitt, “Prostaglandin endoperoxide H syntheses (cyclooxygenases)-1 and -2,” Journal of Biological Chemistry, vol. 271, no. 52, pp. 33157–33160, 1996. View at Scopus
  50. J. Arnold, E. C. De Boer, M. A. O'Donnell, A. Böhle, and S. Brandau, “Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-γ,” Journal of Immunotherapy, vol. 27, no. 2, pp. 116–123, 2004. View at Scopus
  51. M. Horinaga, K. M. Harsch, R. Fukuyama, W. Heston, and W. Larchian, “Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model,” Urology, vol. 66, no. 2, pp. 461–466, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. L. E. DesJardin, T. M. Kaufman, B. Potts, B. Kutzbach, H. Yi, and L. S. Schlesinger, “Mycobacterium tuberculosis-infected human macrophages exhibit enhanced cellular adhesion with increased expression of LFA-1 and ICAM-1 and reduced expression and/or function of complement receptors, FcγRII and the mannose receptor,” Microbiology, vol. 148, no. 10, pp. 3161–3171, 2002. View at Scopus
  53. T. Mustafa, S. Phyu, R. Nilsen, G. Bjune, and R. Jonsson, “Increased expression of Fas ligand on Mycobacterium tuberculosis infected macrophages: a potential novel mechanism of immune evasion by Mycobacterium tuberculosis?” Inflammation, vol. 23, no. 6, pp. 507–521, 1999. View at Scopus
  54. G. E. Diehl, H. H. Yue, and H. H. Yue, “TRAIL-R as a negative regulator of innate immune cell responses,” Immunity, vol. 21, no. 6, pp. 877–889, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. S. Saito and M. Nakano, “Nitric oxide production by peritoneal macrophages of Mycobacterium bovis BCG-infected or non-infected mice: regulatory roles of T lymphocytes and cytokines,” Journal of Leukocyte Biology, vol. 59, no. 6, pp. 908–915, 1996. View at Scopus
  56. V. L. Petricevich and R. C. B. Alves, “Role of cytokines and nitric oxide in the induction of tuberculostatic macrophage functions,” Mediators of Inflammation, vol. 9, no. 6, pp. 261–269, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. S. J. Hawkyard, A. M. Jackson, S. Prescott, K. James, and G. D. Chisholm, “The effect of recombinant cytokines on bladder cancer cells in vitro,” Journal of Urology, vol. 150, no. 2, pp. 514–518, 1993. View at Scopus
  58. S.-C. Choi, H.-M. Oh, and H.-M. Oh, “Soluble factor from murine bladder tumor-2 cell elevates nitric oxide production in macrophages and enhances the taxol-mediated macrophage cytotoxicity on tumor cells,” Cancer Investigation, vol. 21, no. 5, pp. 708–719, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. M. A. O'Donnell, Y. Luo, S. E. Hunter, X. Chen, L. L. Hayes, and S. K. Clinton, “The essential role of interferon-γ during interleukin-12 therapy for murine transitional cell carcinoma of the bladder,” Journal of Urology, vol. 171, no. 3, pp. 1336–1342, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. C. F. Ware, S. VanArsdale, and T. L. VanArsdale, “Apoptosis mediated by the TNF-related cytokine and receptor families,” Journal of Cellular Biochemistry, vol. 60, no. 1, pp. 47–55, 1996. View at Publisher · View at Google Scholar · View at Scopus
  61. S. M. Laster, J. G. Wood, and L. R. Gooding, “Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis,” Journal of Immunology, vol. 141, no. 8, pp. 2629–2634, 1988. View at Scopus
  62. V. Umansky and V. Schirrmacher, “Nitric oxide-induced apoptosis in tumor cells,” Advances in Cancer Research, vol. 82, pp. 107–131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. S. J. Greent, L. F. Scheller, and L. F. Scheller, “Nitric Oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens,” Immunology Letters, vol. 43, no. 1-2, pp. 87–94, 1994. View at Publisher · View at Google Scholar · View at Scopus
  64. V. Kindler, A.-P. Sappino, G. E. Grau, P.-F. Piguet, and P. Vassalli, “The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection,” Cell, vol. 56, no. 5, pp. 731–740, 1989. View at Scopus
  65. A. Zhou, Z. Chen, and Z. Chen, “Exogenous interferon-γ induces endogenous synthesis of interferon-α and -β by murine macrophages for induction of nitric oxide synthase,” Journal of Interferon and Cytokine Research, vol. 15, no. 10, pp. 897–904, 1995. View at Scopus
  66. S. Huguenin, F. Vacherot, J. Fleury-Feith, J.-P. Riffaud, D. K. Chopin, M. Bolla, and M.-C. Jaurand, “Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines,” Cancer Letters, vol. 218, no. 2, pp. 163–170, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. E. Morcos, O. T. Jansson, J. Adolfsson, G. Kratz, and N. Peter Wiklund, “Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines,” Urology, vol. 53, no. 6, pp. 1252–1257, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. O. T. Jansson, E. Morcos, L. Brundin, J. O. N. Lundberg, J. Adolfsson, M. Söderhäll, and N. P. Wiklund, “The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer,” British Journal of Cancer, vol. 78, no. 5, pp. 588–592, 1998. View at Scopus
  69. J. Riemensberger, A. Böhle, and S. Brandau, “IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer,” Clinical and Experimental Immunology, vol. 127, no. 1, pp. 20–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. R. De Waal Malefyt, J. Abrams, B. Bennett, C. G. Figdor, and J. E. De Vries, “Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes,” Journal of Experimental Medicine, vol. 174, no. 5, pp. 1209–1220, 1991. View at Scopus
  71. D. F. Fiorentino, A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra, “IL-10 inhibits cytokine production by activated macrophages,” Journal of Immunology, vol. 147, no. 11, pp. 3815–3822, 1991. View at Scopus
  72. E. Cenci, L. Romani, A. Mencacci, R. Spaccapelo, E. Schiaffella, P. Puccetti, and F. Bistoni, “Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans,” European Journal of Immunology, vol. 23, no. 5, pp. 1034–1038, 1993. View at Scopus
  73. C. Bogdan, Y. Vodovotz, and C. Nathan, “Macrophage deactivation by interleukin 10,” Journal of Experimental Medicine, vol. 174, no. 6, pp. 1549–1555, 1991. View at Scopus
  74. P. Chomarat, J. Banchereau, J. Davoust, and A. K. Palucka, “IL-6 switches the differentiation of monocytes from dendritic cells to macrophages,” Nature Immunology, vol. 1, no. 6, pp. 510–514, 2000. View at Scopus